What is the difference between ARA-290 and Teriparatide?

ARA-290: Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing Teriparatide: Recombinant PTH 1-34; when given intermittently, preferentially activates osteoblasts over osteoclasts; increases bone remodeling and net bone formation; stimulates IGF-1 in bone

Is ARA-290 FDA approved?

ARA-290 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is Teriparatide FDA approved?

Teriparatide is FDA approved (FDA status current as of 2002-11-26). This regulatory status is provided for research and educational context only.

How is ARA-290 administered in research settings?

In research settings, ARA-290 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Teriparatide administered in research settings?

In research settings, Teriparatide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›ARA-290 vs Teriparatide

Peptide Comparison

ARA-290 vs Teriparatide

Name: ARA-290 vs Teriparatide — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Longevity & Cellular peptides.

ARA-290

Cibinetide

LongevityInvestigationalResearch Only

Half-life: ~2 min (IV); ~10–20 min (SC)

17 providers listed

Full ARA-290 profile →

Teriparatide

Forteo

LongevityFDA ApprovedPrescription

Half-life: ~1 hour

3 providers listed

Full Teriparatide profile →

Bottom line

Teriparatide is FDA-approved, while ARA-290 is investigational — the clearest structural difference between them.

Quick Verdict

ARA-290

Half-life

~2 min (IV); ~10–20 min (SC)

Teriparatide

Half-life

~1 hour

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Teriparatide
Further along in FDA review	Teriparatide
Less frequent dosing (longer half-life)	Teriparatide
More provider options (17 vs 3)	ARA-290

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

ARA-290

Teriparatide

Mechanism Family

Longevity & Cellular

Half-life

~2 min (IV); ~10–20 min (SC)

~1 hour

FDA Status

investigational

approved

Admin Routes

subcutaneous, intravenous

subcutaneous

Availability

Research Only

Prescription

Providers

17 listed

3 listed

FDA Update

—

Nov 2002

Avail. Notes

Non-hematopoietic EPO analog (cibinetide) by Araim Pharma. Phase 3 for sarcoidosis peripheral neuropathy; Dutch conditional marketing authorisation applied for. No FDA approval. Investigational.

FDA-approved parathyroid hormone 1-34 analog. Forteo (NDA 021318, Nov 2002) for osteoporosis. Biosimilar Bonsity (NDA 210842, Jan 2020) also approved. Prescription only.

Research Evidence

ARA-290

RCT · 2 key studies · most recent 2026

Teriparatide

Meta-analysis · 4 key studies · most recent 2026

Research Citations

ARA-290

RCT2017 · Investigative Ophthalmology & Visual Science

Cibinetide (ARA 290) reduces small nerve fiber pathology in sarcoidosis patients

Animal2026 · Neurobiol Dis

Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.

Teriparatide

Meta-analysis2026 · J Oral Biosci

The impact of parathyroid hormone supplementation on dental implant osseointegration in osteoporotic subjects…

Meta-analysis2023 · Annals of Internal Medicine

Pharmacological Management of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living…

Cohort2026 · J Orthop

Association between antiosteoporosis medications and risk of sacral fracture after lumbosacral fusion in adul…

Cohort2026 · J Funct Morphol Kinesiol

Biological Augmentation of Reamed Intramedullary Nailing for Aseptic Tibial Shaft Nonunion: An Exploratory Mu…

About ARA-290

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

Research Areas

neuropathic pain relieftissue repairanti-inflammatorymetabolic improvement

About Teriparatide

Recombinant PTH 1-34; when given intermittently, preferentially activates osteoblasts over osteoclasts; increases bone remodeling and net bone formation; stimulates IGF-1 in bone

Research Areas

bone formationbone density increaseosteoporosis reversalfracture risk reduction

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

ARA-290

Reported (Unverified — Pending Clinical Review)

active erythrocytosis

No established clinical contraindications

Teriparatide

Reported (Unverified — Pending Clinical Review)

osteosarcoma risk (2-year limit)Paget's diseaseprior radiation to skeletonhypercalcemia

No established clinical contraindications

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Price (per mg)

ARA-290

$4.95/mg

$3.91 – $5.56 range

34 vendors

View price index →Find providers →

Teriparatide

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

ARA-290

17 listed

Browse directory →

Providers offering

Teriparatide

3 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). ARA-290 vs Teriparatide — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/ara-290/teriparatide

https://peptidebase.io/peptides/compare/ara-290/teriparatide Methodology License Download JSON Download CSV